Romidepsin (Istodax)
Other Medications · Approved since 2009
Description
Romidepsin is a histone deacetylase (HDAC) inhibitor that has been evaluated for colorectal cancer treatment, particularly in patients with microsatellite stable (MSS) tumors. This agent was originally developed as an anti-cancer compound and has shown activity in solid tumors including metastatic colorectal cancer. Romidepsin has been tested both as monotherapy in previously treated advanced colorectal cancer patients and in combination approaches to enhance immune checkpoint inhibitor responses.
Mechanism of Action
Romidepsin selectively inhibits class I histone deacetylases, particularly HDAC1 and HDAC2, leading to increased acetylation of histone proteins and altered gene expression patterns. This epigenetic modification can result in tumor cell cycle arrest, differentiation, and apoptosis while potentially enhancing immune recognition through upregulation of tumor antigens and immune signaling pathways.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Istodax |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use other indication |
| Administration | IV |
| Year Approved | 2009 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.